S-CMC or other thiol donor drug treatment can attenuate the CSE- triggered SUMO modification of HDAC2 in thiol/GSH-dependent manner, which provides a mechanistic explanation for the reversal of glucocorticoid resistance by S-CMC in COPD. Here, HDAC2 is linked to chronic obstructive pulmonary disease.